Goldman Sachs lowered the firm’s price target on Sagimet Biosciences to $23 from $27 and keeps a Buy rating on the shares following the Q1 report. The company’s progress continues across the portfolio, notably for denifanstat in nonalcoholic steatohepatitis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Biosciences Names Thierry Chauche New CFO
- Sagimet Biosciences announces appointment of Chauche as CFO
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
- Carvana upgraded, Block downgraded: Wall Street’s top analyst calls